secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-211935
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImageneBio Q1 net loss $10.6M; cash $117.2M, raised $30M in April private placement
--------------------------------------------------------------------------------

- Net loss of $10.6M for Q1 2026, vs $9.1M in Q1 2025; R&D $6.0M, G&A $6.1M.
- Cash of $117.2M as of March 31; April private placement raised $30M, extending runway into Q1 2028.
- Phase 2b ADAPTIVE trial in AD advancing under amended protocol; topline data anticipated Q4 2027.
- Plan to initiate Phase 2 in alopecia areata in 2026; initial data expected 2028, based on proof-of-concept.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000119312526211935/0001193125-26-211935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000119312526211935/d151394d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-211935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer